Table of Contents:

Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter's Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6 Global Cancer Biomarker Market, By Types
6.1 Introduction
6.2 Protein Biomarker
6.3 Genetic Biomarker
6.4 Others
Chapter 7 Global Cancer Biomarker Market, By Application
7.1 Introduction
7.2 Diagnostic
7.2.1 Imaging
7.2.2 Non- Imaging
7.3 Prognostic
7.4 Therapeutic
Chapter 8 Global Cancer Biomarker Market, By End Users
8.1 Introduction
8.2 Pharma & Biotech Companies
8.3 Diagnostic Tool Companies
8.4 Healthcare IT/Big Data Companies
8.5 Clinical Laboratories
Chapter 9. Global Cancer Biomarker Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 U.K
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa
Chapter 10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 11 Company Profiles
11.1 F. Hoffmann-La Roche AG
11.1.1 Company Overview
11.1.2 Financials
11.1.3 Products
11.1.4 Strategy
11.1.5 Key Developments
11.2 Becton Dickinson
11.2.1 Company Overview
11.2.2 Financials
11.2.3 Products
11.2.4 Strategy
11.2.5 Key Developments
11.3 Abbott Laboratories
11.3.1 Company Overview
11.3.2 Financials
11.3.3 Products
11.3.4 Strategy
11.3.5 Key Developments
11.4 PerkinElmer, Inc.
11.4.1 Company Overview
11.4.2 Financials
11.4.3 Products
11.4.4 Strategy
11.4.5 Key Developments
11.5 Bristol-Myers Squibb
11.5.1 Company Overview
11.5.2 Financials
11.5.3 Products
11.5.4 Strategy
11.5.5 Key Developments
11.6 Bio-Rad Laboratories
11.6.1 Company Overview
11.6.2 Financials
11.6.3 Products
11.6.4 Strategy
11.6.5 Key Developments
11.7 Eli Lilly and Company
11.7.1 Company Overview
11.7.2 Financials
11.7.3 Products
11.7.4 Strategy
11.7.5 Key Developments
11.8 Merck & Co., Inc
11.8.1 Company Overview
11.8.2 Financials
11.8.3 Products
11.8.4 Strategy
11.8.5 Key Developments
11.9 Pfizer Inc.
11.9.1 Company Overview
11.9.2 Financials
11.9.3 Products
11.9.4 Strategy
11.9.5 Key Developments
11.10 GlaxoSmithKline plc.
11.10.1 Company Overview
11.10.2 Financials
11.10.3 Products
11.10.4 Strategy
11.10.5 Key Developments
11.11 QIAGEN N.V
11.11.1 Company Overview
11.11.2 Financials
11.11.3 Products
11.11.4 Strategy
11.11.5 Key Developments
?11.12 Novartis AG
11.12.1 Company Overview
11.12.2 Financials
11.12.3 Products
11.12.4 Strategy
11.12.5 Key Developments
11.13 Thermo Fisher Scientific Inc.
11.13.1 Company Overview
11.13.2 Financials
11.13.3 Products
11.13.4 Strategy
11.13.5 Key Developments
11.14 Illumina Inc.
11.14.1 Company Overview
11.14.2 Financials
11.14.3 Products
11.14.4 Strategy
11.14.5 Key Developments
11.15 Others
Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO's View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Medical End Users Industry
Chapter 13 Appendix